Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai Henlius Biotech, Inc. (2696.HK)
Shanghai, CN
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.21% | -3.52% | -8.91% | +2.16% | -0.80% | +20.07% | +46.84% | +540.19% | +63.88% | +38.52% | +38.52% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | +1 |
| Buy | 8 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+16.5% ★ Q4'25: +29.2% (vs Q4'24)
-
EPS growth Biotechnology: +29.7%-2.7% Q4'25: +0.0% (vs Q4'24)
-
FCF margin FCF growth · Biotechnology: +16.2%+9.1% Q4'25: +0.0% (vs Q4'24)
-
EBIT margin Biotechnology: +0.0%+12.3% ★ Q4'25: +9.9% (vs Q4'24)
-
ROIC Biotechnology: -16.1%+12.0% ★ Q4'25: +11.2% (vs Q4'24)
-
Share dilution Biotechnology: -3.4%+0.5% ★ Q4'25: +0.9% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×3.09× Q4'25: 3.32× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 6 EPS Ana. |
Dec 2027 8 Rev. Ana. 6 EPS Ana. |
Dec 2028 7 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
90.93M
est: 111.81M (-18.7%)
|
587.59M
est: 669.54M (-12.2%)
|
1.68B
est: 1.75B (-3.6%)
|
3.21B
est: 3.11B (+3.4%)
|
5.39B
est: 5.25B (+2.8%)
|
5.72B
est: 5.71B (+0.3%)
|
6.67B
est: 5.95B (+12.0%)
|
8.16B
7.10B – 10.76B
+37.1% YoY
|
8.26B
7.19B – 9.68B
+1.3% YoY
|
9.81B
8.54B – 12.23B
+18.8% YoY
|
12.91B
11.24B – 16.08B
+31.6% YoY
|
| EBITDA |
-744.00M
est: -25.20M (-2,852.9%)
|
-814.06M
est: -3.76B (+78.4%)
|
-671.74M
est: -9.10B (+92.6%)
|
-310.61M
est: -15.72B (+98.0%)
|
911.33M
est: 3.06B (-70.3%)
|
1.15B
est: -97.21B (+101.2%)
|
1.16B
est: 3.48B (-66.5%)
|
4.76B
4.15B – 6.28B
+37.1% YoY
|
4.82B
4.20B – 5.65B
+1.3% YoY
|
5.73B
4.99B – 7.14B
+18.8% YoY
|
7.54B
6.56B – 9.39B
+31.6% YoY
|
| EBIT |
-826.50M
est: -32.04M (-2,479.7%)
|
-949.84M
est: -3.70B (+74.3%)
|
-871.92M
est: -8.95B (+90.3%)
|
-588.22M
est: -15.46B (+96.2%)
|
631.70M
est: 2.99B (-78.9%)
|
866.50M
est: -95.58B (+100.9%)
|
817.12M
est: 3.40B (-75.9%)
|
4.65B
4.05B – 6.14B
+37.1% YoY
|
4.71B
4.10B – 5.52B
+1.3% YoY
|
5.60B
4.87B – 6.97B
+18.8% YoY
|
7.36B
6.41B – 9.18B
+31.6% YoY
|
| Net Income |
-875.47M
est: -727.19M (-20.4%)
|
-993.54M
est: -3.92B (+74.6%)
|
-984.05M
est: -9.48B (+89.6%)
|
-695.26M
est: -203.18M (-242.2%)
|
546.02M
est: 644.01M (-15.2%)
|
820.47M
est: 751.92M (+9.1%)
|
805.64M
est: 742.85M (+8.5%)
|
873.54M
753.49M – 2.97B
+17.6% YoY
|
844.54M
321.23M – 1.39B
-3.3% YoY
|
1.07B
802.10M – 1.58B
+27.1% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
220.52M
est: 54.81M (+302.3%)
|
436.29M
est: 328.22M (+32.9%)
|
800.87M
est: 855.86M (-6.4%)
|
1.40B
est: 1.52B (-7.9%)
|
2.14B
est: 2.21B (-3.3%)
|
2.29B
est: 2.40B (-4.8%)
|
2.65B
est: 2.51B (+5.8%)
|
3.44B
2.99B – 4.53B
+37.1% YoY
|
3.48B
3.03B – 4.08B
+1.3% YoY
|
4.13B
3.60B – 5.15B
+18.8% YoY
|
5.44B
4.73B – 6.78B
+31.6% YoY
|
| EPS |
-1.76
est: -1.34 (-31.5%)
|
-1.88
est: -1.62 (-16.1%)
|
-1.83
est: -1.20 (-52.1%)
|
-1.28
est: -1.04 (-23.2%)
|
1.01
est: 1.18 (-14.8%)
|
1.51
est: 1.08 (+39.9%)
|
1.48
est: 1.61 (-8.0%)
|
2.21
1.38 – 5.44
+37.1% YoY
|
1.71
0.59 – 2.55
-22.5% YoY
|
2.19
1.47 – 2.90
+28.2% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Genomics Immunology and Healthcare ETF IDNA | 0.55% | 1.08M | 0.47% |
| 2 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.13% | 1.54M | 0.40% |
| 3 | iShares Ageing Population UCITS ETF AGED.L | 0.10% | 916.0K | 0.40% |
| 4 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.04% | 47.6K | 0.42% |
| 5 | State Street SPDR S&P China ETF GXC | 0.02% | 71.7K | 0.59% |
| 6 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 80.7K | 0.44% |
| 7 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 6.5K | 0.15% |
| 8 | Amundi Prime Emerging Markets UCITS ETF DR (C) PRAM.L | 0.01% | 135.2K | 0.10% |
| 9 | FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE | 0.01% | 24.1K | 0.58% |
| 10 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 685.5K | 0.07% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jun Zhu | Chief Executive Officer & Executive Director | 13M | male |
| Shi-Kau Liu | Co-founder & Head of Strategy Advisory Committee | 7M | — |
| Junhua Li | Senior Vice President & Chief Human Resources Officer | — | female |
| Miaojie Chen | Vice President of Legal & Compliance | — | female |
| Ping Cao | Senior VP & Chief Business Development Officer | — | female |
| Wallis Zeng | Vice President of Sales & Oncology Business Unit | — | male |
| Wei Huang | President | — | female |
| Wei-Dong Jiang | Co-Founder & Co-Head of Innovative Advisory Committee | — | — |
| Xinjun Guo | Senior Vice President | — | male |
| Yan Wang | GM of Public Relations, Joint Company Secretary & Board Secretary | — | female |
| Yingbo Mao | Vice President & Chief Financial Officer | — | male |
| Huang Wei | President | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2696.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
